A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability
Bevacizumab (BVZ) is a monoclonal antibody that binds to human vascular endothelial growth factor A (VEGF-A) and inhibits the interaction between VEGF-A and VEGF receptors, thus blocking the angiogenesis. Repeated intravitreal injections of BVZ for the treatment of ocular pathologies that present an...
Main Authors: | Daniela Chirio, Elena Peira, Simona Sapino, Giulia Chindamo, Simonetta Oliaro-Bosso, Salvatore Adinolfi, Chiara Dianzani, Francesca Baratta, Marina Gallarate |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/4/560 |
Similar Items
-
Assessment of<i> </i>In-Situ Gelling Microemulsion Systems Upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab
by: Elena Peira, et al.
Published: (2021-02-01) -
Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizuma
by: Kanwal Zareen Abbasi
Published: (2016-03-01) -
Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats
by: Yan Lu, et al.
Published: (2014-02-01) -
The Short-Term Effect of Intravitreal Bevacizumab Injection on Intraocular Pressure
by: Şehnaz Özçalışkan, et al.
Published: (2014-10-01) -
Acute Endophthalmitis Caused by Leuconostoc spp. following Intravitreal Bevacizumab Injection
by: Supreet Singh, et al.
Published: (2017-10-01)